BHA
Antioxidant; Fragrance Ingredient; MASKING
Also listed as
ANTIOXYNE B; ANTRANCINE 12; EEC NO. E320; EMBANOX; NIPANTIOX 1-F; PROTEX; SUSTANE 1-F; TENOX BHA
Given the incomplete information made available by companies and the government, EWG provides additional information on personal care product ingredients from the published scientific literature. The chart below indicates that research studies have found that exposure to this ingredient -- not the products containing it -- caused the indicated health effect(s) in the studies reviewed by Skin Deep researchers. Actual health risks, if any, will vary based on the level of exposure to the ingredient and individual susceptibility -- information not available in Skin Deep.
| This ingredient: | |
 | Cancer |
 | Developmental/reproductive toxicity |
 | Violations, restrictions & warnings |
| Allergies/immunotoxicity |
 | Contamination concerns |
| Other strong concerns for this ingredient: Organ system toxicity (non-reproductive) |
| Other moderate concerns for this ingredient: Endocrine disruption, Persistence and bioaccumulation, Biochemical or cellular level changes |
| Lesser or emerging concerns for this ingredient: Neurotoxicity, Ecotoxicology, Data gaps |
|
See products containing BHA | |
About BHA: BHA is a mixture of isomers of tertiary butyl-substituted 4-methoxyphenols. It consists chieflyof 3-t-butyl-4-hydroxyanisole with lesser amounts of 2-t-butyl-4-hydroxyanisole. It conforms generally tothe formula:
BHA has reported used in the following product types: lipstick (162); eye shadow (86); facial moisturizer/treatment (57); lip liner (48); anti-aging (33); mascara (31); foundation (30); skin fading/lightener (29); lip gloss (25); eye liner (25)
Allergies/immunotoxicity
| type of concern | product conditions | reference |
| Known human immune system toxicant | National Library of Medicine HazMap |
Violations, restrictions & warnings
| type of concern | product conditions | reference |
| Violation of government restrictions - Banned or found unsafe for use in cosmetics | EU Banned and Restricted Fragrances |
Cancer
| type of concern | product conditions | reference |
| Possible human carcinogen | products for use on the lips | NTP Report on Carcinogens, 11th Edition |
| Possible human carcinogen | products for use on the lips | California EPA Proposition 65 |
| Limited evidence of carcinogenicity | products for use on the lips | Int'l Agency for Research on Cancer (IARC) - Carcinogens |
| Possible carcinogen | Environmental Canada Domestic Substance List | |
| show more | ||
Organ system toxicity (non-reproductive)
| type of concern | product conditions | reference |
| Known human toxicant | EU Banned and Restricted Fragrances | |
| Classified as a high human health priority | Environmental Canada Domestic Substance List | |
| One or more animal studies show liver effects at very low doses | RTECS®- British Journal of Cancer 1982 | |
| show more | ||
Persistence and bioaccumulation
| type of concern | product conditions | reference |
| Persistent, bioaccumulative in wildlife | OSPAR PBTs - Substances of Possible Concern | |
| show more | ||
Endocrine disruption
| type of concern | product conditions | reference |
| Limited evidence of endocrine disruption | Japanese National Institute of Health Sciences, 1993 | |
| show more | ||
Neurotoxicity
| type of concern | product conditions | reference |
| One or more animal studies show brain and nervous system effects at moderate doses | RTECS®- Kenkyu Nenpo--Tokyo-toritsu Eisei Kenkyusho 1970 | |
| show more | ||
Biochemical or cellular level changes
| type of concern | product conditions | reference |
| One or more animal studies show biochemical changes at very low doses where the human health implications are not yet well understood | RTECS®- British Journal of Cancer 1982 | |
| show more | ||
Developmental/reproductive toxicity
| type of concern | product conditions | reference |
| One or more animal studies show reproductive effects at high doses | RTECS®- Toxicology and Applied Pharmacology 2004 | |
| show more | ||
Ecotoxicology
| type of concern | product conditions | reference |
| Wildlife and environmental toxicity | Illinois EPA Chemicals Associated with Endocrine System | |
| show more | ||
Multiple, additive exposure sources
| type of concern | product conditions | reference |
| Designated as safe for general or specific, limited use in food | FDA Food Additive Status | |
| Designated as safe for general or specific, limited use in food | FDA Everything Added to Food |
Data gaps
| type of concern | product conditions | reference |
| Risk assessment method deficiencies and data gaps - Maximum reported "as used" concentration is basis of safety assessment by industry safety panel (Cosmetic Ingredient Review, CIR) - implicit safe concentration limit in product | Cosmetic Ingredient Review Assessments | |
| 1,363 studies on toxicity in PubMed see search results -> | PubMed |
Government, industry, academic studies and classifications
| government/industry list/academic study | appears on list as | classification(s) |
| FDA Food Additive Status | BHA | • AOX/FS • GRAS (generally recognized as safe) - use in food presumed safe based either on a history of use before 1958 or on published scientific evidence; need not be approved by the FDA prior to use in food; most have not limit for use but must conform to good manufacturing practices; some GRAS substances have quantitative limit for use in foods; by definition under Sec 201(s) of FD&C Act, not food additives • 0.02% - Of fat or oil content • including essential (volatile) oil • or food • including oleomargarine - refers to part number under Title 21 Code of Federal Regulations 166 • Margarine • Food additive: antioxidant • Food additive: food additive for which a petition has been filed and a regulation issued • 10 parts per million • alone or w/BHT - In potato granules - CFR172.110 • 32 parts per million - In mixed diced • glazed fruits - CFR172.110 • 50 parts per million • alone |
| Cosmetic Ingredient Review Assessments | BHA | •Safe as used in cosmetics according to industry panel (Cosmetic Ingredient Review, CIR) •Maximum reported "as used" concentration is basis of safety assessment by industry safety panel (Cosmetic Ingredient Review, CIR) - implicit safe concentration limit in product |
| Cosmetic Ingredient Review Assessments | BUTYLATED HYDROXYANISOLE | •Safe as used in cosmetics according to industry panel (Cosmetic Ingredient Review, CIR) •Maximum reported "as used" concentration is basis of safety assessment by industry safety panel (Cosmetic Ingredient Review, CIR) - implicit safe concentration limit in product |
| FDA Everything Added to Food | BUTYLATED HYDROXYANISOLE | • Fully up-to-date toxicology information has been sought. |
| Illinois EPA Chemicals Associated with Endocrine System | TERT-BUTYLHYDROXYANISOLE | •EPA: suspected endocrine disruptor |
| EU Banned and Restricted Fragrances | BHA | Prohibited. Should not be used as a fragrance ingredient. Based on the depigmenting effect (pc to IFRA). |
| National Library of Medicine HazMap | BUTYLATED HYDROXYANISOLE | •Skin Sensitizer - An agent that can induce an allergic reaction in the skin or lungs: Yes; |
| Int'l Agency for Research on Cancer (IARC) - Carcinogens | BUTYLATED HYDROXYANISOLE (BHA) | •IARC Group 2B: possible human carcinogen (International Agency for Research on Carcinogens) |
| NTP Report on Carcinogens, 11th Edition | BUTYLATED HYDROXYANISOLE (BHA) | •Reasonably anticipated to be a human carcinogen (National Toxicology Program classification) |
| Our Stolen Future Endocrine Disruptors | BUTYLATED HYDROXYANISOLE (BHA) | • |
| OSPAR PBTs - Substances of Possible Concern | (1,1DIMETHYLETHYL)4METHOXYPHENOL | •Persistent, bioaccumulative toxicant - Oslo-Paris (OSPAR) Convention for the Protection of the Marine Environment of the North-East Atlantic, chemical of concern |
| California EPA Proposition 65 | BUTYLATED HYDROXYANISOLE | •Carcinogen: California Proposition 65 |
| Japanese National Institute of Health Sciences, 1993 | BUTYLATED HYDROXYANISOLE (BHA) | •Endocrine toxicity hazards: suspected |
| European Commission on Endocrine Disruption | TERT.-BUTYLHYDROXYANISOLE (BHA) | HH-CAT1;WF-CAT1 |
| Environmental Canada Domestic Substance List | PHENOL, (1,1-DIMETHYLETHYL)-4-METHOXY- | •This chemical was deemed a high human health priority even though it did not meet the strict criteria of the categorization exercise of CEPA. The chemical was flagged for suspected carcinogenic concerns. |
| RTECS®- Australian Journal of Experimental Biology and Medical Science 1959 | BHA | • liver - Changes in liver weight (rat TDLo) |
| RTECS®- Australian Journal of Experimental Biology and Medical Science 1961 | BHA | • endocrine system - Changes in adrenal weight (rat TDLo) • blood - Changes in serum composition (eg., TP, bilirubin, cholesterol) (rat TDLo) |
| RTECS®- British Journal of Cancer 1982 | BHA | • liver - Changes in liver weight (mouse TDLo) • biochemical - Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.) (mouse TDLo) • liver - Other changes (mouse TDLo) |
| RTECS®- Bulletin of Environmental Contamination and Toxicology 1985 | BHA | • biochemical - Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.) (rat TDLo) • liver - Other changes (rat TDLo) |
| RTECS®- Cancer Letters (Shannon, Ireland) 1986 | BHA | • mutagenic - Positive mutation assay: Unscheduled DNA Synthesis (rat orl) |
| RTECS®- Cancer Letters (Shannon, Ireland) 1999 | BHA | • cancer - Active as anti-cancer agent (mouse TDLo) • cancer - Protects against induction of experimental tumors (mouse TDLo) • respiratory - Tumors (mouse TDLo) |
| RTECS®- Cancer Letters (Shannon, Ireland) 1999 | BHA | • cancer - Active as anti-cancer agent (rat TDLo) • cancer - Protects against induction of experimental tumors (rat TDLo) • liver - Tumors (rat TDLo) |
| RTECS®- Cancer Letters (Shannon, Ireland) 1986 | BHA | • mutagenic - Positive mutation assay: Unscheduled DNA Synthesis (rat orl) |
| RTECS®- Cancer Research 1986 | BHA | • cancer - respiratory neoplasms (rat TD) |
| RTECS®- Carcinogenesis (London) 1992 | BHA | • mutagenic - Positive mutation assay: DNA Inhibition ( human hla) |
| RTECS®- Carcinogenesis (London) 1983 | BHA | • cancer - Cells (cultured) transformed (rat TD) • cancer - kidney or renal system tumors (rat TD) |
| RTECS®- Carcinogenesis (London) 1992 | BHA | • mutagenic - Positive mutation assay: DNA Inhibition ( human hla) |
| RTECS®- Federation Proceedings, Federation of American Societies for Experimental Biology 1972 | BHA | • reproductive - Behavioral (mouse TDLo) |
| RTECS®- FEMS Microbiology Letters 1982 | BHA | • mutagenic - Positive mutation assay: Mutation in Micro-organism (other micro-organisms ) |
| RTECS®- FEMS Microbiology Letters 1982 | BHA | • mutagenic - Positive mutation assay: Mutation in Micro-organism (other micro-organisms ) |
| RTECS®- Food and Chemical Toxicology 1986 | BHA | • liver - Changes in liver weight (monkey TDLo) • gastrointestinal - Other changes (monkey TDLo) • biochemical - Other enzymes (monkey TDLo) |
| RTECS®- Food and Chemical Toxicology 2004 | BHA | • liver - Changes in liver weight (rat TDLo) • biochemical - Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.) (rat TDLo) • liver - Other changes (rat TDLo) |
| RTECS®- Food and Cosmetics Toxicology 1972 | BHA | • liver - Changes in liver weight (monkey TDLo) • liver - Other changes (monkey TDLo) • biochemical - Phosphatases (monkey TDLo) |
| RTECS®- Food and Cosmetics Toxicology 1965 | BHA | • liver - Changes in liver weight (rat TDLo) • biochemical - Phosphatases (rat TDLo) |
| RTECS®- Gann 1982 | BHA | • cancer - gastrointestinal tumor formations - equivocal (rat TD) • cancer - gastrointestinal tumors (rat TDLo) |
| RTECS®- Gann 1983 | BHA | • cancer - gastrointestinal neoplasms (hamster TD) |
| RTECS®- Japanese Journal of Cancer Research 1986 | BHA | • cancer - gastrointestinal tumor formations - equivocal (mouse TDLo) • cancer - gastrointestinal tumors (hamster TDLo) |
| RTECS®- Japanese Journal of Cancer Research 1986 | BHA | • cancer - gastrointestinal neoplasms (rat TD) |
| RTECS®- Japanese Journal of Cancer Research 1993 | BHA | • mutagenic - endocrine system tumors (rat TD) • cancer - gastrointestinal tumors (rat TD) |
| RTECS®- Journal of the American Oil Chemists' Society 1977 | BHA | • broad systemic - Broad systemic toxicity (rabbit LD50) |
| RTECS®- Journal of the National Cancer Institute 1977 | BHA | • mutagenic - Positive mutation assay: Sister Chromatid Exchange (hamster fbr) |
| RTECS®- Journal of the National Cancer Institute 1977 | BHA | • mutagenic - Positive mutation assay: Sister Chromatid Exchange (hamster fbr) |
| RTECS®- Kenkyu Nenpo--Tokyo-toritsu Eisei Kenkyusho 1970 | BHA | • brain and nervous system - Altered sleep time (including change in righting reflex) (mouse LD50) • brain and nervous system - Ataxia (mouse LD50) • liver - Changes in liver weight (rat TDLo) • blood - Changes in serum composition (eg., TP, bilirubin, cholesterol) (rat TDLo) • endocrine system - Changes in thyroid weight (rat TDLo) • respiratory - Respiratory stimulation (mouse LD50) |
| RTECS®- Mutation Research 1996 | BHA | • mutagenic - Positive mutation assay: DNA Damage (rat lvr) |
| RTECS®- Mutation Research 2002 | BHA | • mutagenic - Positive mutation assay: DNA Damage (mouse orl) |
| RTECS®- Mutation Research 1996 | BHA | • mutagenic - Positive mutation assay: DNA Damage (rat lvr) |
| RTECS®- Mutation Research 2002 | BHA | • mutagenic - Positive mutation assay: DNA Damage (mouse orl) |
| RTECS®- Neurobehavioral Toxicology and Teratology 1981 | BHA | • reproductive - Growth statistics (rat TDLo) • reproductive - Weaning or lactation index (rat TDLo) |
| RTECS®- Toxicology and Applied Pharmacology 2004 | BHA | • reproductive - Uterus, cervix, vagina (rat TDLo) • endocrine system - Changes in adrenal weight (rat TDLo) • liver - Changes in liver weight (rat TDLo) • endocrine system - Changes in prostate weight (rat TDLo) • endocrine system - Changes in uterine weight (rat TDLo) |
| RTECS®- Toxicology In Vitro 1991 | BHA | • mutagenic - Positive mutation assay: DNA Inhibition (hamster lng) |
| RTECS®- Toxicology In Vitro 1991 | BHA | • mutagenic - Positive mutation assay: DNA Inhibition (hamster lng) |
| RTECS®- Toxicology Letters 2003 | BHA | • biochemical - Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.) (rat TDLo) • biochemical - Other transferases (rat TDLo) |
| RTECS®- Toxicology Letters 1985 | BHA | • blood - Hemorrhage (rat LD50) • metabolic - Weight loss or decreased weight gain (rat TDLo) • respiratory - Changes in lung weight (rat TDLo) • blood - Other hemolysis with or without anemia (rat TDLo) |
| RTECS®- Toxicology Letters 1986 | BHA | • cancer - gastrointestinal tumors (rat TD) |
| RTECS®- Toxicology 2005 | BHA | • developmental - Delayed effects (rat TDLo) • reproductive - Mating performance (rat TDLo) • reproductive - Other effects in male (rat TDLo) |
references
| government/industry list/academic study | reference |
| FDA Food Additive Status | FDA (U.S. Food and Drug Administration) 2006. Food Additive Status List. Downloaded from http://www.cfsan.fda.gov/%7Edms/opa-appa.html, Oct 16, 2006. |
| Cosmetic Ingredient Review Assessments | CIR (Cosmetic Ingredient Review). 2006. CIR Compendium, containing abstracts, discussions, and conclusions of CIR cosmetic ingredient safety assessments. Washington DC. |
| FDA Everything Added to Food | FDA (U.S. Food and Drug Administration). 2008. EAFUS [Everything Added to Food]: A Food Additive Database. FDA Office of Food Safety and Applied Nutrition. |
| Illinois EPA Chemicals Associated with Endocrine System | Illinois EPA (Illinois Environmental Protection Agency). 2000. Preliminary list of chemicals associated with endocrine system effects in animals and humans (*) or in vitro (+). In EPA (U.S. Environmental Protection Agency) 2000. Handbook for Non-Cancer Health Effects Valuation, Appendix C. |
| EU Banned and Restricted Fragrances | SCCPNFP (Scientific Committee On Cosmetic Products And Non-Food Products). 1999. Opinion Concerning Fragrance Allergy In Consumers. . SCCNFP/0017/98 Final, December 1999; and SCCPNFP (Scientific Committee On Cosmetic Products And Non-Food Products). 2000. An Initial List Of Perfumery Materials Which Must Not Form Part Of Fragrances Compounds Used In Cosmetic Products. SCCNFP/0320/00, final May 2000. |
| National Library of Medicine HazMap | NLM (National Library of Medicine). 2006. HazMap — Occupational Exposure to Hazardous Agents. |
| Int'l Agency for Research on Cancer (IARC) - Carcinogens | IARC (International Agency for Research on Cancer). 2008. Overall Evaluations of Carcinogenicity to Humans, as evaluated in IARC Monographs Volumes 1-99 (a total of 935 agents, mixtures and exposures). |
| NTP Report on Carcinogens, 11th Edition | NTP (National Toxicology Program). 2005. Report on Carcinogens, Eleventh Edition; U.S. Department of Health and Human Services, Public Health Service, National Toxicology Program. |
| Our Stolen Future Endocrine Disruptors | Colborn T, D Dumanoski, JP Myers. 2006. Widespread Pollutants with Endocrine-disrupting Effects. Updated from original listing in "Our Stolen Future" (1996). |
| OSPAR PBTs - Substances of Possible Concern | OSPAR (Oslo-Paris). 2002. OSPAR List of Substances of Possible Concern. Secondary OSPAR List of Substances of Possible Concern. Secondary OSPAR. Place Published, OSPAR Convention for the Protection of the Marine Environement of North-East Atlanic. |
| California EPA Proposition 65 | California EPA (California Environmental Protection Agency). 9/2008. Office of Environmental Health Hazard Assessment. Safe Drinking Water and Toxic Enforcement Act of 1986. Chemicals known to the State to cause cancer or reproductive toxicity. |
| Scorecard.org Toxicity Information | Japanese National Institute of Health Sciences. Lists of Paradigmatic Chemicals. http://www.nihs.go.jp/hse/endocrine-e/paradigm/paradigm.html, World Wildlife Fund. Our Stolen Future. Widespread Pollutants with Endocrine-disrupting Effects. http://www.ourstolenfuture.org/Basics/chemlist.htm. The WWF list is derived from references detailed at http://www.ourstolenfuture.org/Sources/chemsources.htm and was originally published in: Colborn, T., F.S. vom Saal, and A.M. Soto. Developmental Effects of Endocrine-Disrupting Chemicals In Wildlife and Humans. Environmental Health Perspectives 101(5): 378-384. 1993. |
| European Commission on Endocrine Disruption | EU (European Union)- Strategy for Endocrine Disrupters 2007. Commision on endocrin disruption requested by the European Parliament in 1998. |
| Environmental Canada Domestic Substance List | EC (Environment Canada). 2008. Domestic Substances List Categorization. Canadian Environmental Protection Act (CEPA) Environmental Registry. |
| RTECS®- Australian Journal of Experimental Biology and Medical Science 1959 | RTECS®- Australian Journal of Experimental Biology and Medical Science. (Adelaide, S.A., Australia) V.1-64, 1924-86. 37,533,1959 |
| RTECS®- Australian Journal of Experimental Biology and Medical Science 1961 | RTECS®- Australian Journal of Experimental Biology and Medical Science. (Adelaide, S.A., Australia) V.1-64, 1924-86. 39,353,1961 |
| RTECS®- British Journal of Cancer 1982 | RTECS®- British Journal of Cancer. (Macmillan Press Ltd., Houndmills, Basingstoke, Hants. RG21 2XS, UK) V.1- 1947- 45,935,1982 |
| RTECS®- Bulletin of Environmental Contamination and Toxicology 1985 | RTECS®- Bulletin of Environmental Contamination and Toxicology. (Springer-Verlag New York, Inc., Service Center, 44 Hartz Way, Secaucus, NJ 07094) V.1- 1966- 34,787,1985 |
| RTECS®- Cancer Letters (Shannon, Ireland) 1986 | RTECS®- Cancer Letters (Shannon, Ireland). (Elsevier Scientific Pub. Ireland Ltd., POB 85, Limerick, Ireland) V.1- 33,119,1986 |
| RTECS®- Cancer Letters (Shannon, Ireland) 1999 | RTECS®- Cancer Letters (Shannon, Ireland). (Elsevier Scientific Pub. Ireland Ltd., POB 85, Limerick, Ireland) V.1- 1975- 137,123,1999 |
| RTECS®- Cancer Letters (Shannon, Ireland) 1999 | RTECS®- Cancer Letters (Shannon, Ireland). (Elsevier Scientific Pub. Ireland Ltd., POB 85, Limerick, Ireland) V.1- 1975- 143,173,1999 |
| RTECS®- Cancer Letters (Shannon, Ireland) 1986 | RTECS®- Cancer Letters (Shannon, Ireland). (Elsevier Scientific Pub. Ireland Ltd., POB 85, Limerick, Ireland) V.1- 1975- 33,119,1986 |
| RTECS®- Cancer Research 1986 | RTECS®- Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut Sts., Philadelphia, PA 19106) V.1- 1941- 46,165,1986 |
| RTECS®- Carcinogenesis (London) 1992 | RTECS®- Carcinogenesis (London). (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK) V.1- 1980- 13,2389,1992 |
| RTECS®- Carcinogenesis (London) 1983 | RTECS®- Carcinogenesis (London). (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK) V.1- 1980- 4,895,1983 |
| RTECS®- Carcinogenesis (London) 1992 | RTECS®- Carcinogenesis (London). (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK) V.1- 13,2389,1992 |
| RTECS®- Federation Proceedings, Federation of American Societies for Experimental Biology 1972 | RTECS®- Federation Proceedings, Federation of American Societies for Experimental Biology. (Bethesda, MD) V.1-46, 1942-87. 31,596,1972 |
| RTECS®- FEMS Microbiology Letters 1982 | RTECS®- FEMS Microbiology Letters. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1977- 14,183,1982 |
| RTECS®- FEMS Microbiology Letters 1982 | RTECS®- FEMS Microbiology Letters. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 14,183,1982 |
| RTECS®- Food and Chemical Toxicology 1986 | RTECS®- Food and Chemical Toxicology. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523) V.20- 1982- 24,1197,1986 |
| RTECS®- Food and Chemical Toxicology 2004 | RTECS®- Food and Chemical Toxicology. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523) V.20- 1982- 42,899,2004 |
| RTECS®- Food and Cosmetics Toxicology 1972 | RTECS®- Food and Cosmetics Toxicology. (London, UK) V.1-19, 1963-81. For publisher information, see FCTOD7. 10,769,1972 |
| RTECS®- Food and Cosmetics Toxicology 1965 | RTECS®- Food and Cosmetics Toxicology. (London, UK) V.1-19, 1963-81. For publisher information, see FCTOD7. 3,457,1965 |
| RTECS®- Gann 1982 | RTECS®- Gann. Japanese Journal of Cancer Research. (Tokyo, Japan) V.1-75, 1907-84. For publisher information, see JJCREP. 73,332,1982 |
| RTECS®- Gann 1983 | RTECS®- Gann. Japanese Journal of Cancer Research. (Tokyo, Japan) V.1-75, 1907-84. For publisher information, see JJCREP. 74,459,1983 |
| RTECS®- Japanese Journal of Cancer Research 1986 | RTECS®- Japanese Journal of Cancer Research. (Elsevier Science Pub. BV, POB 211, 1000 AE Amsterdam, Netherlands) V.76- 1985- 77,1083,1986 |
| RTECS®- Japanese Journal of Cancer Research 1986 | RTECS®- Japanese Journal of Cancer Research. (Elsevier Science Pub. BV, POB 211, 1000 AE Amsterdam, Netherlands) V.76- 1985- 77,854,1986 |
| RTECS®- Japanese Journal of Cancer Research 1993 | RTECS®- Japanese Journal of Cancer Research. (Elsevier Science Pub. BV, POB 211, 1000 AE Amsterdam, Netherlands) V.76- 1985- 84,237,1993 |
| RTECS®- Journal of the American Oil Chemists' Society 1977 | RTECS®- Journal of the American Oil Chemists' Society. (Champaign, IL) V.24-56, 1947-79. 54,239,1977 |
| RTECS®- Journal of the National Cancer Institute 1977 | RTECS®- Journal of the National Cancer Institute. (Washington, DC) V.1-60, 1940-78. For publisher information, see JJIND8. 58,1635,1977 |
| RTECS®- Journal of the National Cancer Institute 1977 | RTECS®- Journal of the National Cancer Institute. (Washington, DC) V.1-60, 1940-78. For publisher information, see JJIND8. 58,1635,1977 |
| RTECS®- Kenkyu Nenpo--Tokyo-toritsu Eisei Kenkyusho 1970 | RTECS®- Kenkyu Nenpo--Tokyo-toritsu Eisei Kenkyusho. Annual Report of Tokyo Metropolitan Research Laboratory of Public Health. (Tokyo-toritsu Eisei Kenkyusho, 24-1, 3-chome, Hyakunin-cho, Shin-juku-ku, Tokyo 160, Japan) V.1- 1949/50- 22,231,1970 |
| RTECS®- Mutation Research 1996 | RTECS®- Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 368,59,1996 |
| RTECS®- Mutation Research 2002 | RTECS®- Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 519,103,2002 |
| RTECS®- Mutation Research 1996 | RTECS®- Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- -1964 368,59,1996 |
| RTECS®- Mutation Research 2002 | RTECS®- Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- -1964 519,103,2002 |
| RTECS®- Neurobehavioral Toxicology and Teratology 1981 | RTECS®- Neurobehavioral Toxicology and Teratology. (Fayetteville, NY) V.3-8, 1981-86. For publisher information, see NETEEC. 3,321,1981 |
| RTECS®- Toxicology and Applied Pharmacology 2004 | RTECS®- Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- 197,230,2004 |
| RTECS®- Toxicology In Vitro 1991 | RTECS®- Toxicology In Vitro. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523) V.1- 5,549,1991 |
| RTECS®- Toxicology In Vitro 1991 | RTECS®- Toxicology In Vitro. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523) V.1- 1987- 5,549,1991 |
| RTECS®- Toxicology Letters 2003 | RTECS®- Toxicology Letters. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1977- 145,281,2003 |
| RTECS®- Toxicology Letters 1985 | RTECS®- Toxicology Letters. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1977- 27,15,1985 |
| RTECS®- Toxicology Letters 1986 | RTECS®- Toxicology Letters. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1977- 31(Suppl),207,1986 |
| RTECS®- Toxicology 2005 | RTECS®- Toxicology. (Elsevier Scientific Pub. Ireland, Ltd., POB 85, Limerick, Ireland) V.1- 1973- 208,49,2005 |
"RTECS®" is a United States trademark owned and licensed under authority of the U.S. Government, by and through MDL Information Systems, Inc.
Favorites basket
No items in basket.
Skin Deep User Tools BETA
Looking for a product report that we don't have in Skin Deep? Sign up to enter it into the Skin Deep database and leave product reviews.
SKIN DEEP NEEDS YOUR HELP
We always want Skin Deep to be free to the public, but delivering high-quality research costs time and money. Help by donating just the cost of a bar of soap or bottle of shampoo.
WANT TO KNOW MORE?
Stay informed with email updates on toxics in everyday products and how they can affect your health.
SKIN DEEP NEWS
'I just wanted to let you know how much Skin Deep has changed my daughter's (and my) life.'
—Melissa M., Michigan